Atria Investments Inc Buys 734 Shares of Avantor, Inc. (NYSE:AVTR)

Atria Investments Inc raised its stake in shares of Avantor, Inc. (NYSE:AVTR) by 4.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,925 shares of the company’s stock after buying an additional 734 shares during the quarter. Atria Investments Inc’s holdings in Avantor were worth $412,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Swedbank AB purchased a new position in Avantor during the first quarter worth about $2,707,000. Sound Shore Management Inc. CT bought a new position in shares of Avantor in the second quarter worth approximately $76,412,000. Seven Eight Capital LP purchased a new stake in Avantor in the second quarter valued at approximately $642,000. New York State Teachers Retirement System purchased a new stake in Avantor in the third quarter valued at approximately $8,473,000. Finally, Allspring Global Investments Holdings LLC lifted its position in Avantor by 35.1% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,157,855 shares of the company’s stock valued at $24,547,000 after purchasing an additional 300,579 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

Avantor Price Performance

Shares of NYSE AVTR opened at $20.36 on Friday. The firm has a market cap of $13.86 billion, a P/E ratio of 44.26, a PEG ratio of 2.39 and a beta of 1.35. Avantor, Inc. has a twelve month low of $19.59 and a twelve month high of $28.00. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The company has a 50 day moving average of $24.01 and a 200 day moving average of $23.89.

Insider Buying and Selling

In other news, CAO Steven W. Eck sold 3,525 shares of the stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the transaction, the chief accounting officer now owns 29,544 shares in the company, valued at $740,372.64. This represents a 10.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Wells Fargo & Company dropped their price target on Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Barclays cut their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Robert W. Baird decreased their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Avantor in a research note on Thursday, September 26th. Finally, TD Cowen lifted their target price on shares of Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $27.57.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.